eFFECTOR Therapeutics, Inc. Research and Development Expense
eFFECTOR Therapeutics, Inc. reported Research and Development Expense of $5.31 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-05-09
- eFFECTOR Therapeutics, Inc. research and development expense for the quarter ending 2024-03-31 was $5.31M, a 19.72% decline year-over-year.
- eFFECTOR Therapeutics, Inc. research and development expense for the quarter ending 2023-12-31 was $6.07M, a 8.66% decline year-over-year.
- eFFECTOR Therapeutics, Inc. research and development expense for the quarter ending 2023-09-30 was $5.36M, a 19.26% decline year-over-year.
- eFFECTOR Therapeutics, Inc. research and development expense for the quarter ending 2023-06-30 was $4.88M, a 29.46% decline year-over-year.
- eFFECTOR Therapeutics, Inc. research and development expense for fiscal 2023 was $22.92M, a 1.69% decline from fiscal 2022.
- eFFECTOR Therapeutics, Inc. research and development expense for fiscal 2022 was $23.31M, a 16.82% increase from fiscal 2021.
- eFFECTOR Therapeutics, Inc. research and development expense for fiscal 2021 was $19.96M, a 8.59% decline from fiscal 2020.
- eFFECTOR Therapeutics, Inc. research and development expense for fiscal 2020 was $21.83M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $5.31M 10-Q · filed 2024-05-09 | $11.38M derived: sum of 2 quarters · filed 2024-05-09 | $16.73M derived: sum of 3 quarters · filed 2024-05-09 | $21.62M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $6.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $11.43M derived: sum of 2 quarters · filed 2024-03-26 | $16.31M derived: sum of 3 quarters · filed 2024-03-26 | $22.92M 10-K · filed 2024-03-26 |
| 2023-09-30 | $5.36M 10-Q · filed 2023-11-13 | $10.24M derived: sum of 2 quarters · filed 2023-11-13 | $16.84M 10-Q · filed 2023-11-13 | $23.50M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $4.88M 10-Q · filed 2023-08-08 | $11.49M 10-Q · filed 2023-08-08 | $18.14M derived: sum of 3 quarters · filed 2024-05-09 | $24.77M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $6.61M 10-Q · filed 2024-05-09 | $13.26M derived: sum of 2 quarters · filed 2024-05-09 | $19.89M derived: sum of 3 quarters · filed 2024-05-09 | $26.81M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $6.65M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $13.28M derived: sum of 2 quarters · filed 2024-03-26 | $20.20M derived: sum of 3 quarters · filed 2024-03-26 | $23.31M 10-K · filed 2024-03-26 |
| 2022-09-30 | $6.63M 10-Q · filed 2023-11-13 | $13.55M derived: sum of 2 quarters · filed 2023-11-13 | $16.66M 10-Q · filed 2023-11-13 | $23.06M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $6.92M 10-Q · filed 2023-08-08 | $10.03M 10-Q · filed 2023-08-08 | $16.43M derived: sum of 3 quarters · filed 2023-08-08 | $21.45M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $3.11M 10-Q · filed 2023-05-09 | $9.51M derived: sum of 2 quarters · filed 2023-05-09 | $14.53M derived: sum of 3 quarters · filed 2023-05-09 | $18.60M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $6.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $11.42M derived: sum of 2 quarters · filed 2023-03-08 | $15.49M derived: sum of 3 quarters · filed 2023-03-08 | $19.96M 10-K · filed 2023-03-08 |
| 2021-09-30 | $5.02M 10-Q · filed 2022-11-07 | $9.09M derived: sum of 2 quarters · filed 2022-11-07 | $13.56M 10-Q · filed 2022-11-07 | $18.16M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $4.07M 10-Q · filed 2022-08-09 | $8.54M 10-Q · filed 2022-08-09 | $13.14M derived: sum of 3 quarters · filed 2022-08-09 | $19.92M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $4.47M 10-Q · filed 2022-05-10 | $9.07M derived: sum of 2 quarters · filed 2022-05-10 | $15.85M derived: sum of 3 quarters · filed 2022-05-10 | $20.68M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $11.38M derived: sum of 2 quarters · filed 2022-03-16 | $16.21M derived: sum of 3 quarters · filed 2022-03-16 | $21.83M 10-K · filed 2022-03-16 |
| 2020-09-30 | $6.78M 10-Q · filed 2021-11-08 | $11.61M derived: sum of 2 quarters · filed 2021-11-08 | $17.23M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $4.83M 8-K · filed 2021-08-31 | $10.45M 8-K · filed 2021-08-31 |